Can flecainide be used for conversion or maintenance of atrial flutter?

Flecainide Use in Atrial Flutter: Exercise Extreme Caution

Flecainide is NOT recommended for atrial flutter and should generally be avoided due to the serious risk of paradoxical 1:1 atrioventricular conduction leading to dangerously rapid ventricular rates, plus its poor efficacy for flutter termination. 1

Why Flecainide Fails in Atrial Flutter

Poor Conversion Efficacy

The fundamental problem is that flecainide is ineffective at terminating atrial flutter:

• Conversion rates are dismal: Only 1 out of 8 patients (13%) with atrial flutter converted to sinus rhythm with flecainide, compared to much higher rates in atrial fibrillation 2, 3
• Flecainide prolongs the flutter cycle length significantly (from 226ms to 317ms) but this slowing paradoxically worsens the situation rather than terminating the arrhythmia 2
• The drug slows atrial conduction without adequately prolonging refractoriness—the exact opposite of what's needed to break the flutter circuit 2

The Dangerous 1:1 Conduction Problem

This is the critical safety issue: Flecainide slows the atrial flutter rate just enough to allow 1:1 AV conduction, potentially doubling the ventricular rate from a controlled 150 bpm to a life-threatening 300 bpm 4, 1, 5.

• The FDA label explicitly warns about this: "patients treated with flecainide acetate for atrial flutter have been reported with 1:1 atrioventricular conduction due to slowing the atrial rate" 1
• Case reports document ventricular fibrillation occurring after cardioversion attempts in patients on flecainide with 1:1 flutter 5
• This complication can be fatal and requires emergency defibrillation 5

When Flecainide Might Be Considered (Rarely)

If you absolutely must use flecainide in a patient with atrial flutter:

1. Mandatory AV nodal blockade FIRST: Give beta-blockers or non-dihydropyridine calcium channel blockers at least 30 minutes before flecainide to prevent 1:1 conduction 4, 6, 7

2. Exclude all contraindications:

   • No structural heart disease (especially post-MI, CAD, LV dysfunction, significant LVH) 8
   • No heart failure (NYHA class II-IV or LVEF <30%) 8
   • No conduction abnormalities (QRS >120ms, bundle branch block) 8
   • Normal QTc (<500ms) 9

3. Hospital monitoring required: Initial doses must be given with continuous cardiac monitoring 4

Better Alternatives for Atrial Flutter

Use dofetilide or ibutilide instead—these Class III agents are specifically more effective for flutter:

• Dofetilide: 70% conversion rate in flutter (7 of 10 patients) versus 9% with flecainide 4, 2
• Ibutilide: Effective for flutter cardioversion with appropriate QT monitoring 4, 10
• Amiodarone: Safer in structural heart disease, though slower conversion 4

These drugs prolong refractoriness without the dangerous conduction slowing that characterizes flecainide's mechanism.

The CAST Trial Warning

The FDA black box warning stems from the Cardiac Arrhythmia Suppression Trial showing 5.1% mortality with flecainide versus 2.3% with placebo in post-MI patients 1. While this studied ventricular arrhythmias, it underscores flecainide's proarrhythmic potential in any patient with structural heart disease—a common finding in chronic atrial flutter patients.

Clinical Bottom Line

For atrial flutter specifically: Choose electrical cardioversion or Class III antiarrhythmics (dofetilide, ibutilide, amiodarone) over flecainide. If flecainide is already on board when flutter develops, the risk of 1:1 conduction is present and requires immediate rate control with AV nodal blockers before any intervention 1, 5.